Ramucirumab (IMC-1121B): a novel attack on angiogenesis

Future Oncology
Jennifer SpratlinJohn R Mackey

Abstract

Angiogenesis is a critical hallmark of malignancy, and attempts to inhibit this process have characterized the age of biologic anticancer therapies for solid tumors. VEGF receptor-2 is the premier receptor responsible for many of the cancer-driven VEGF-induced spectrum of biologic changes, including modification of blood vessel structure and function, proliferation and migration. Unlike all clinically approved angiogenesis inhibitors, the fully human monoclonal antibody ramucirumab (IMC-1121B) specifically and potently inhibits VEGF receptor-2. Phase I clinical trials have shown safety across a wide range of ramucirumab doses with impressive, albeit early, evidence of both stable disease and partial responses in a variety of tumor types. In this article, we review the current data on ramucirumab and make comparisons with commercially available antiangiogenic agents.

References

Oct 1, 1996·Cytokine & Growth Factor Reviews·M Klagsbrun, P A D'Amore
Nov 14, 1997·Nature Medicine·M SkobeN E Fusenig
Sep 24, 1999·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·N Ferrara
Sep 23, 2000·Nature·P Carmeliet, R K Jain
Oct 12, 2000·Nature Cell Biology·G BergersD Hanahan
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S GordonD Adelman
May 23, 2001·Drug Discovery Today·D J. HicklinP Bohlen
Nov 16, 2001·Biochemical Society Transactions·L H Hurley
Jan 5, 2002·International Journal of Cancer. Journal International Du Cancer·Dan LuZhenping Zhu
Jul 13, 2002·Cancer·Nina S Kadan-LottickJames G Gurney
Oct 3, 2002·Journal of the National Cancer Institute·Gordon C JaysonUNKNOWN European Organisation for Research and Treatment of Cancer Biological Therapeutic Development Group
Jan 25, 2003·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Hans-Peter Gerber, Napoleone Ferrara
Dec 24, 2003·The Cancer Journal·Diane D Davey
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk StrumbergSiegfried Seeber
May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne L ThomasWilliam P Steward
May 21, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S N HoldenH I Hurwitz
Aug 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey W ClarkHeinz-Josef Lenz
Nov 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandrine FaivreEric Raymond
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Mar 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laura Q M Chow, S Gail Eckhardt
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Tomohide TamuraNagahiro Saijo
Apr 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce J GiantonioUNKNOWN Eastern Cooperative Oncology Group Study E3200

❮ Previous
Next ❯

Citations

Jul 25, 2012·Cancer Chemotherapy and Pharmacology·Saroj KunnakkatAshwatha Narayana
Mar 15, 2012·Langenbeck's Archives of Surgery·L V KlotzChristiane J Bruns
Apr 21, 2012·Future Oncology·Christina E StevensonKazuaki Takabe
Jul 3, 2013·Proceedings of the National Academy of Sciences of the United States of America·Yunlong YangYihai Cao
May 31, 2013·Future Oncology·Roopma WadhwaJaffer A Ajani
Dec 21, 2012·Future Oncology·Brigitte C M Haberkorn, Ferry A L M Eskens
Mar 13, 2014·Expert Review of Anticancer Therapy·Roopma WadhwaJaffer A Ajani
May 23, 2012·Expert Opinion on Investigational Drugs·Teresa TroianiFloriana Morgillo
Feb 28, 2013·Expert Opinion on Biological Therapy·Giuseppe BronteAntonio Russo
Aug 7, 2012·Expert Opinion on Biological Therapy·Afsaneh Barzi, Heinz-Josef Lenz
Dec 12, 2012·Expert Opinion on Emerging Drugs·Erika MartinelliFortunato Ciardiello
Jul 16, 2014·Expert Opinion on Biological Therapy·Geraldine O'Sullivan Coyne, Mauricio Burotto
Apr 29, 2015·Molecular Immunology·J M RedmanL M Weiner
Apr 16, 2016·Expert Opinion on Drug Delivery·Megan GrundyRobert Carlisle
Jun 8, 2012·International Journal of Surgical Oncology·Dae Dong Kim, Cathy Eng
May 5, 2016·Expert Review of Anticancer Therapy·Asuncion Diaz-SerranoRocio Garcia-Carbonero
Aug 18, 2017·International Journal of Molecular Sciences·Deok-Hoon KongSukmook Lee
Dec 13, 2017·Future Oncology·Panagiotis J VlachostergiosScott T Tagawa
Jan 19, 2012·Clinical Medicine Insights. Oncology·Tzu-Fei Wang, Albert Craig Lockhart
Jun 18, 2016·International Journal of Oncology·Xiaofeng DouXinhui Su
Mar 4, 2020·Cancers·Nicola J NasserAbed Agbarya
Jun 17, 2020·Chemical Society Reviews·Saeid KargozarMasoud Mozafari
Nov 7, 2015·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Haiming LuoWeibo Cai
Mar 9, 2021·Internal Medicine·Tadanobu AragakiTetsuya Yoda

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
ELISA
xenograft
biopsy

Clinical Trials Mentioned

NCT00533702
NCT00515697
NCT00735696
NCT00862784
NCT00627042
NCT00721162
NCT01017731
NCT00683475
NCT00895180
NCT00703326

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.